Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.

To our Shareholders,

September 2008 will be a pivotal month for our organization as we expect to initiate the first clinical use of our Hemopurifier in HIV-infected individuals. We believe the Hemopurifier can address the clearance of all HIV strains, thus curbing the proliferation of mutant strains that cause patients to fail their drug regimens. A therapeutic approach able to inhibit drug resistance has long been hoped for by the HIV-AIDS community. We hope to fill that treatment void.

We are also moving towards completion of our human safety study being conducted at the Fortis Hospital in Delhi, India. While the pace of patient enrollment was slower than anticipated, I am pleased to disclose that our treatment protocol has been expanded to include patients infected with Hepatitis-C virus (HCV). As a result, preliminary HCV data, including changes in viral load resulting from Hemopurifier treatment, should be available for dissemination in the coming weeks. The opportunity for new antiviral strategies to fight HCV is significant, as approximately 180 million people worldwide (3% of the world’s population) are HCV infected. According to the World Health Organization (WHO), only 30-50% of infected patients beneficially respond to the established pegylated interferon-ribavirin treatment standard. Recognizing the exceptional challenge in treating HCV, we are cautiously optimistic that human data will reinforce the potential of our Hemopurifier to improve treatment outcomes. Based on the magnitude of the HCV market opportunity, we also recognize that clinical stage organizations with promising HCV treatment candidates have been rewarded with enviable public market valuations.

Beyond pivotal milestone activities expected this month, it should be noted that our team has already been quite productive in 2008. In studies conducted at collaborating research centers, the in vitro effectiveness of our Hemopurifier to rapidly capture highly fatal H5N1 Avian Influenza Virus (bird flu), the reconstructed Spanish Flu Virus of 1918, Monkey Pox Virus, and West Nile Virus have all been documented since the beginning of the year. Thus, further reinforcing the broad-spectrum capabilities of our technology. Additionally, we expanded our robust intellectual property estate; provided a formal response to a pending U.S. government biodefense contract; and have initiated development of a family of pipeline products based on techniques and methods evolved in the creation of our core Hemopurifier technology. This pipeline presently includes therapeutic filtration devices to remove high-dose chemotherapy agents, and growth factors that increase the spread of metastases in cancer.

Thus far in 2008, we have progressed our mission to establish the industry to treat infectious disease and cancer with therapeutic filtration devices. It is my hope that outcomes from near-term human treatment milestones will accelerate the evolution of our organization and establish appropriate shareholder value. On behalf of our team at Aethlon Medical, I thank you for your continued support.

Very truly yours,

James A. Joyce

Chairman, CEO